The North America Diabetic Retinopathy Market would witness market growth of 10.8% CAGR during the forecast period (2021-2027).
The market is also being driven by an increase in the prevalence of diabetes, a rise in the geriatric population, an increase in the incidence of diabetes-related blindness, and a greater focus on earlier detection to control diseases. In contrast, the advent of combination therapies for the therapeutics of diabetic macular edema, as well as expanding markets in various countries all over the world, are likely to create numerous prospects for the growth of the diabetic retinopathy market over the coming years.
The treatment of diabetic retinopathy is determined by the symptoms, age, and overall health statistics of the patient. It can also be defined by the severity of the ailment. If advanced retinopathy is treated before the retina is significantly damaged, people in advanced stages of retinopathy have a fair chance of retaining their eyesight. The vitreous that occupies the center of the eye is removed during vitrectomy surgery.
According to the Centers for Disease Control and Prevention (CDC), around 100 million Americans have diabetes, which is one of the leading causes of blindness. The regional market is also growing as people become more aware of sophisticated solutions for treating diabetic retinopathy. The diabetic retinopathy market in North America is highly competitive. For example, Bayer AG is a leading pharmaceutical company in the United States that has dominated the market by producing high-quality diabetic retinopathy treatments. As a result, new entrants should weigh the risks of entering into a competitive market. The regional market is also growing because of the favorable reimbursement policies and the rising diabetes prevalence. One of the key factors leading to the huge regional share is the high market penetration of anti-VEGF medications such as Avastin, Elea, and Lucentis.
The US market dominated the North America Diabetic Retinopathy Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $2,103.7 Million by 2027. The Canada market anticipated to grow at a CAGR of 13.3% during (2021 - 2027). Additionally, The Mexico market would display a CAGR of 12.3% during (2021 - 2027).
Based on Type, the market is segmented into Proliferative and Diabetic Macular Edema (DME). Based on Treatment Type, the market is segmented into Anti VEGF Drug, Steroid Implants, Laser Surgeries, and Vitrectomy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Diabetic Retinopathy Market is Estimated to reach $7.7 Billion by 2027, at a CAGR of 11.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Allergan PLC (Abbvie, Inc.), Bayer AG, Alimera Sciences, Inc., Novartis AG, Pfizer, Inc., F-Hoffmann-La Roche Ltd., Ampio Pharmaceuticals-us, KOWA CO., LTD., Regeneron Pharmaceuticals, Inc., and Bausch Health Companies, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Proliferative
- Diabetic Macular Edema (DME)
By Treatment Type
- Anti VEGF Drug
- Steroid Implants
- Laser Surgeries
- Vitrectomy
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Allergan PLC (Abbvie, Inc.)
- Bayer AG
- Alimera Sciences, Inc.
- Novartis AG
- Pfizer, Inc.
- F-Hoffmann-La Roche Ltd.
- Ampio Pharmaceuticals-us
- KOWA CO., LTD.
- Regeneron Pharmaceuticals, Inc.
- Bausch Health Companies, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Diabetic Retinopathy Market, by Type
1.4.2 North America Diabetic Retinopathy Market, by Treatment Type
1.4.3 North America Diabetic Retinopathy Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Diabetic Retinopathy Market
Chapter 4. North America Diabetic Retinopathy Market by Type
4.1 North America Proliferative Market by Country
4.2 North America Diabetic Macular Edema (DME) Market by Country
Chapter 5. North America Diabetic Retinopathy Market by Treatment Type
5.1 North America Anti VEGF Drug Market by Country
5.2 North America Steroid Implants Market by Country
5.3 North America Laser Surgeries Market by Country
5.4 North America Vitrectomy Market by Country
Chapter 6. North America Diabetic Retinopathy Market by Country
6.1 US Diabetic Retinopathy Market
6.1.1 US Diabetic Retinopathy Market by Type
6.1.2 US Diabetic Retinopathy Market by Treatment Type
6.2 Canada Diabetic Retinopathy Market
6.2.1 Canada Diabetic Retinopathy Market by Type
6.2.2 Canada Diabetic Retinopathy Market by Treatment Type
6.3 Mexico Diabetic Retinopathy Market
6.3.1 Mexico Diabetic Retinopathy Market by Type
6.3.2 Mexico Diabetic Retinopathy Market by Treatment Type
6.4 Rest of North America Diabetic Retinopathy Market
6.4.1 Rest of North America Diabetic Retinopathy Market by Type
6.4.2 Rest of North America Diabetic Retinopathy Market by Treatment Type
Chapter 7. Company Profiles
7.1 Alimera Sciences, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.1.5.2 Geographical Expansions:
7.2 F. Hoffmann-La Roche Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Approvals and Trials:
7.3 Bausch Health Companies, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.3.5.2 Approvals and Trials:
7.4 Bayer AG
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Approvals and Trials:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.6 Novartis AG
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Allergan PLC (AbbVie, Inc.)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.8 Regeneron Pharmaceuticals, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expense
7.8.3.1 Approvals and Trials:
7.9 Ampio Pharmaceuticals, Inc.
7.9.1 Company Overview
7.10. Kowa Company, Ltd.
7.10.1 Company Overview
TABLE 1 North America Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 2 North America Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 3 North America Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 4 North America Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 5 North America Proliferative Market by Country, 2017 - 2020, USD Million
TABLE 6 North America Proliferative Market by Country, 2021 - 2027, USD Million
TABLE 7 North America Diabetic Macular Edema (DME) Market by Country, 2017 - 2020, USD Million
TABLE 8 North America Diabetic Macular Edema (DME) Market by Country, 2021 - 2027, USD Million
TABLE 9 North America Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 10 North America Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 11 North America Anti VEGF Drug Market by Country, 2017 - 2020, USD Million
TABLE 12 North America Anti VEGF Drug Market by Country, 2021 - 2027, USD Million
TABLE 13 North America Steroid Implants Market by Country, 2017 - 2020, USD Million
TABLE 14 North America Steroid Implants Market by Country, 2021 - 2027, USD Million
TABLE 15 North America Laser Surgeries Market by Country, 2017 - 2020, USD Million
TABLE 16 North America Laser Surgeries Market by Country, 2021 - 2027, USD Million
TABLE 17 North America Vitrectomy Market by Country, 2017 - 2020, USD Million
TABLE 18 North America Vitrectomy Market by Country, 2021 - 2027, USD Million
TABLE 19 North America Diabetic Retinopathy Market by Country, 2017 - 2020, USD Million
TABLE 20 North America Diabetic Retinopathy Market by Country, 2021 - 2027, USD Million
TABLE 21 US Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 22 US Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 23 US Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 24 US Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 25 US Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 26 US Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 27 Canada Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 28 Canada Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 29 Canada Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 30 Canada Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 31 Canada Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 32 Canada Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 33 Mexico Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 34 Mexico Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 35 Mexico Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 36 Mexico Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 37 Mexico Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 38 Mexico Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 39 Rest of North America Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 40 Rest of North America Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 41 Rest of North America Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 42 Rest of North America Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 43 Rest of North America Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 44 Rest of North America Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 45 Key Information – Alimera Sciences, Inc.
TABLE 46 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 47 key information – Bausch Health Companies, Inc.
TABLE 48 Key Information – Bayer AG
TABLE 49 Key Information – Pfizer, Inc.
TABLE 50 Key Information – Novartis AG
TABLE 51 Key Information – Allergan PLC
TABLE 52 Key Information – Regeneron Pharmaceuticals, Inc.
TABLE 53 Key Information – Ampio Pharmaceuticals, Inc.
TABLE 54 Key Information – Kowa Company, Ltd.
List of Figures
FIG 1 Methodology for the research
FIG 2 Recent strategies and developments: Alimera Sciences, Inc.